Verastem Inc. (VSTM) rose 33% in Post-Market Trading after the company's new drug application (NDA) received priority review status from the USA Food and Drug Administration (FDA).
VSTM美股盘后涨超33%
VSTM's Post-Market Trading rose over 33%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated